Our identification of Tsa cells as both biomarkers and therapeutic targets bridges the gap between experimental neuroimmunology and clinical stroke management, offering a paradigm for mechanistically informed immunomodulation in cerebrovascular diseases. This evidence concerns the gene PRDX2 and Stroke.